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AdenocarcinomaAnaplastic lymphoma kinase (ALK)-positive lung cancers are generally diagnosed at an advanced clinical stage.
Herein, we report a case of an ALK-positive lung cancer patient who had a microlesion of this tumor type. The
patient was a 51-year-old woman without a smoking history. Computed tomography performed during a lung
cancer screening program showed a 7 × 5-mm subpleural nodule with an irregular border in the right lower
lobe. The background lung parenchyma was almost normal. Serum tumor marker levels were not elevated. His-
tological assessment showed destructive growth in the center of the lesion, as conﬁrmed using Victoria blue-
hematoxylin and eosin staining and immunostaining for CD34 and D2-40; however, at the other site, the
tumormainly showed intra-alveolar growthwithminor lepidic growth. The tumor cells were positive for thyroid
transcription factor-1 and ALK. Fluorescent in situ hybridization of the tumor revealed an ALK gene spilt. Accord-
ingly, the tumor was diagnosed as ALK-positive lung cancer. ALK-positive lung cancer presents diverse histolog-
ical architectures in the early phase.ital, 1275-53 Y
. This is an open a
plastic lymph
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ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Aberrant expression of anaplastic lymphomakinase (ALK) due to re-
arrangement of the ALK gene causes a speciﬁc type of adenocarcinoma
of the lung, namely, ALK-positive lung cancer [1]. Clinically, ALK-
positive lung cancers are aggressive, and currently, most patients are di-
agnosed with locally advanced or metastatic disease [2]. Therefore, a
microlesion of ALK-positive lung cancer has not been fully described
histopathologically. It is important to characterize the microlesions of
this tumor type in order tomake the diagnosis and to determine the ap-
propriate treatment regimen. Here, we report a case of ALK-positive
lung cancer showing a microlesion of this tumor type and describe its
histopathological characteristics.
2. Case report
The patientwas a 51-year-old asymptomatic womanwithout a histo-
ry of smoking. Computed tomography (CT) performed during a lung can-
cer screening program revealed a 7 × 5-mm subpleural nodule with an
irregular border in the right lower lobe (Fig. 1). The background lung pa-
renchyma was almost normal. Levels of serum tumor markers, includingasuzukacho-
ccess article under
oma kinase-poscarcinoembryonic antigen, sialyl SSEA-1 antigen, squamous cell carcino-
ma antigen, cytokeratin 19 fragment, and pro-gastrin-releasing peptide,
were within the normal limits. The results of other laboratory studies
were almost normal. The patient was diagnosed with early-phase lung
cancer. CT-guided tumor marking was performed. Subsequently, video-
assisted thoracic wedge resection of the tumor was performed. Macro-
scopic examination of the resected specimen revealed localized indenta-
tion of the visceral pleura (Fig. 2a). On the cut surface of the specimen, a
tan-white tumor (diameter, 5 × 4 mm) was adjacent to the pleura, and
the visceral pleura retracted towards the lesion (Fig. 2b). The surgical
margin was macroscopically negative. Microscopically, the tumor
showed a nodular growth pattern without capsulation at a low magniﬁ-
cation (Fig. 3a). The center of the tumor showed densely intra-alveolar
growth (Fig. 3b). Peripherally, the tumor had lepidic growth along the
alveolar wall (Fig. 3c). Elastic ﬁbers of the alveolar wall were diminished
in the center of the tumor, but were observed at the periphery with
Victoria blue-hematoxylin and eosin staining. Transition from an
alveolar-preserved area to an alveolar-destructive area was also evident
(Fig. 3d). Immunostaining for CD34 (Fig. 3e) and D2-40 (Fig. 3f) showed
the same results. At the center of the alveolar-destructive area, the tumor
cells had high nuclear atypia (Fig. 3g). The tumor cells were positive for
thyroid transcription factor-1 (TTF-1) (Fig. 4a), ALK (Fig. 4b),
E-cadherin, cytokeratin (CK) 7, epithelial membrane antigen, napsin A,
β-catenin, MSH2, MLH1, and MUC1. The cells were also sporadically
positive for p53. The Ki-67 mitotic index was 8% (Fig. 4c). The tumorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Preoperative computed tomography (CT) ﬁndings. A 7 × 5-mm subpleural nodule
with an irregular border in the right lower lobe (arrow) is seen. The background lung pa-
renchyma is almost normal. The area enclosedby thedotted line is highlighted in the inset.
2 T. Kon et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxcells were negative for CK20, p63, p40, MUC2, MUC5AC, and MUC6. Fur-
thermore, ﬂuorescent in situ hybridization of the tumor revealed an ALK
gene split (Fig. 4d). Based on these results, we diagnosed the tumor as a
microlesion of ALK-positive lung cancer. The postoperative course was
uneventful without any adjuvant therapy. One year after surgery, the pa-
tient was doing well without any signs of recurrence.
3. Discussion
We present a case of a very small lesion of ALK-positive lung cancer.
Aberrant expression of ALK due to rearrangement of the ALK gene is
known to cause speciﬁc types of adenocarcinomas of the lung, namely,
ALK-positive lung cancer [1]. This type of lung cancer accounts for
6.7% of non-small lung cancers [1]. ALK-positive lung cancer exhibits
certain histology, such as an acinar pattern with prominent mucin pro-
duction, a mixed papillary pattern, and a solid pattern with signet-ring
cells [3–9]. This type of lung tumor is thought to be derived from cells
of the terminal respiratory unit because of positive reactivity for TTF-1
[10]. However, clinically, ALK-positive lung cancers are aggressive, and
currently, most patients are diagnosed with locally advanced or meta-
static disease [2]. Therefore, the reported histopathological features of
ALK-positive lung cancer are based on data from advanced stage
patients [1,3–9]. The average size of ALK-positive lung cancer fromFig. 2. Resected lung tumor specimen. Macroscopic examination of the resected specimen reve
imen, a tan-white tumor (diameter, 5 × 4 mm) (arrowhead) is adjacent to the pleura, and th
negative.
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(2016), http://dx.doi.org/10.1016/j.ehpc.2016.04.001previous reports was larger than 2 cm (Table 1). On the other hand,
the lesion in our case was less than 1 cm in diameter (0.7 × 0.5 mm
on CT and 0.5 × 0.4 cm on macroscopic examination). Therefore, the
ALK-positive lung cancermicrolesion in this case is an important contri-
bution considering the known information about ALK-positive lung
cancer.
ALK-positive lung cancer could exhibit diverse histological architec-
ture in the early phase. On the basis of information given in previous re-
ports, ALK-positive lung cancer shows diverse histological patterns,
including lepidic predominant, acinar predominant, papillary predomi-
nant, and solid predominant patterns. However, these histological char-
acteristics were observed in relatively advanced lesions [3–9]. In our
patient, the tumor showed destructive growth (Fig. 3d–f) with highly
atypical nuclei (Fig. 3g) in the cells in the center of the tumor. However,
these ﬁndings were seen in a small part of the tumor. The tumormainly
showed intra-alveolar growth (Fig. 3b)withminor lepidic growth at the
periphery (Fig. 3c). It is notable that the microlesion of ALK-positive
lung cancer in our case showed such diverse histological architecture
in the early phase.
A small non-mucinous bronchioloalveolar carcinoma with ALK im-
munoreactivity was previously reported [11]. The authors retrospec-
tively collected 49 adenocarcinoma samples from patients who were
younger than 50 years of age to conﬁrm the frequency of ALK-positive
lung adenocarcinoma in young patients at their hospital [11]. They
found three ALK-positive adenocarcinomas, and one of themmeasured
8 × 6 mm and was located adjacent to the pleura. The histological ap-
pearance was identical to that of bronchioloalveolar carcinoma, show-
ing lepidic growth along the alveolar wall [11]. These ﬁndings differ
from our case; in our case, the tumor size was smaller than that previ-
ously reported [11]. In contrast to the bronchioloalveolar pattern ob-
served in the previous study [11], our case showed diverse histological
architecture, including alveolar wall destruction with highly atypical
cells (Fig. 3d–g), intra-alveolar growth (Fig. 3b), and lepidic growth
along the alveolar wall (Fig. 3c). Therefore, the early histopathogenesis
of ALK-positive lung cancer needs to be elucidated.
When small lung cancer lesions exhibit a diverse histological ap-
pearance, investigation for ALK immunoreactivity and/or performing
ﬂuorescent in situ hybridization forALK translocation are recommended
for diagnosing ALK-positive lung cancer. Similar to advanced stage dis-
ease [7], early phase ALK-positive lung cancer could present with di-
verse histological architecture; in turn, this diverse histological
architecture could be helpful in predicting ALK-positive lung cancer.
Whether ALK-positive cancer will metastasize in the early phase is not
well understood. Therefore, characterization of this tumor in the early
phase is required to reveal its natural course. Furthermore,als localized indentation of the visceral pleura (arrow) (a). On the cut surface of the spec-
e visceral pleura retracted towards the lesion (b). The surgical margin is macroscopically
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Fig. 3. Histopathological examination of the lung tumor. Microscopically, the tumor shows a nodular growth pattern without capsulation at a low magniﬁcation (a; ×12.5). The tumor
mainly shows intra-alveolar growth (b; ×400). Lepidic growth of the tumor along the alveolar wall is seen peripherally (c; ×400). Elastic ﬁbers of the alveolar wall are diminished in
the center of the tumor, but are observed in the periphery on Victoria blue-hematoxylin and eosin staining (VB-H$_amp_$amp;E). Transition from an alveolar-preserved area to an alve-
olar-destructive area is also evident (d; ×100). Immunostaining for CD34 (e; ×100) and D2-40 (f; ×100) also shows the same results. The center of the alveolar destructive area shows
tumor cells with high nuclear atypia (g; ×400).
3T. Kon et al. / Human Pathology: Case Reports xxx (2016) xxx–xxximmunostaining and ﬂuorescent in situ hybridization are also recom-
mended because ALK is a novel drug target, and this cancer is highly re-
sponsive to tyrosine kinase inhibitors such as crizotinib [12,13].
Conﬁrmation of ALK-positivity would broaden the choice of therapy, in-
cluding treatment with tyrosine kinase inhibitors in cases of metastasis.
In addition, the present case showed the following MUC expres-
sion proﬁle: MUC1+/MUC5AC−/MUC6−. Mucins are high-
molecular-weight glycoproteins synthesized by a broad range ofPlease cite this article as: T. Kon, et al., An anaplastic lymphoma kinase-pos
(2016), http://dx.doi.org/10.1016/j.ehpc.2016.04.001epithelial tissues, and characterizing their tissue distribution is high-
ly signiﬁcant in diagnostic surgical pathology [14]. There have been
no reports describing mucin expression proﬁles of ALK-positive
lung cancer. Seventeen of 21 (81%) lung adenocarcinomas were pos-
itive for MUC1, but were negative for MUC5AC [14]. These results
were consistent with the results of our case. Further studies to de-
scribe the mucin expression proﬁles of ALK-positive lung cancer
are required.itive lung cancermicrolesion: A case report, Human Path Case Reports
Fig. 4. Results of immunohistochemical analyses and ﬂuorescent in situ hybridization (FISH). The tumor is positive for thyroid transcription factor-1 (TTF-1) (a; ×400) and ALK (b; ×400).
Ki-67 is sporadically positive (c; ×400). The Ki-index is 8%. FISH of the tumor revealed an ALK gene split (d).
4 T. Kon et al. / Human Pathology: Case Reports xxx (2016) xxx–xxxIn conclusion, we describe a case of a microlesion of ALK-positive
lung cancer. This type of cancer is usually detected at a relatively ad-
vanced stage. Based on our experience with this case, ALK-positive
lung cancer could present with diverse histological architecture in the
early phase.
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Tumor sizes of anaplastic lymphoma kinase-positive lung cancers from previous studies
and from this report.
Reference Number of
patients
Size Comment
Wong DW,
et al. [3]
13 4 cm (range: 2–11 cm) –
Yoshida A,
et al. [4]
54 2.2 cm (interquartile
range: 1.7–3.5 cm)
–
Nishino M,
et al. [5]
104 N.A. Number of Stage IA cases
was 2/104 (1.9%)
Kim H, et al.
[6]
80 3.25 (standard
deviation: 1.85 cm)
–
Choi IH,
et al. [7]
205 N.A. Number of Stage IA cases
was 30/205 (15%)
Our case 1 0.5 cm × 0.4 cm –
Abbreviation: N/A, not applicable.
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